Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Jul 27, 2022 2:21pm
123 Views
Post# 34854485

RE:RE:Th1902 and 5-FU resistance in colorectal cancer treatment

RE:RE:Th1902 and 5-FU resistance in colorectal cancer treatment

Nice job with some primary research for us all. I like her view it is a useful target but don't have enough of a biology background to know what she's pointing out to us.  Always good to have someone outside our sphere confirm it is an interesting and prospective target for cancer treatments.


jeffm34 wrote: Some comments from the researcher when asked about potential of TH1902 given her findings. 

https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.15752
 

First of all, thank you for your interest in my work on sortilin and its implication in the development and progression of CRC as well as in the resistance to treatments, especially to 5-FU. 
 
A cytotoxic targeting Sortilin seems very interesting and promising. Indeed, I had observed that sortilin could be a major player in the resistance of CRC cells to 5-FU, a molecule that has been the "basis" of chemotherapy protocols for years, particularly for the treatment of CRC. Indeed, its expression is considerably increased in 5-FU resistant cells. My work also focused on the CSC aspect: I had started to hypothesize that sortilin could be linked to these cells, especially in high grade tumors. This opened very interesting and promising perspectives. 
 
Finally, in order to try to go further and understand how/why sortilin expression could be increased in 5-FU resistant cells, I had started experiments showing that, resistant cells had a significant disruption of the Golgi, that sortilin seemed to be accumulated inside and that its overexpression could be related to a decrease of ATF-3 expression. 
 
I also noticed that all this was specific to sortilin (e.g. no variation in SorLA expression). 

I noticed that Sortilin was overexpressed at several levels: 
- membrane networks (subcellular fractionations): mainly plasma membrane + Golgi network
- nuclei
 
I also noticed that sortilin was secreted in the culture supernatants 
 
 
This is a very short summary of the main information I can bring you. Do not hesitate to contact me if needed: I will be happy to work again on a project involving Sortiline and CRC! 


<< Previous
Bullboard Posts
Next >>